I tend to jump to this section these days - Unfortunately think we might need to raise next year even with R&D rebate, If we wish to retain a buffer. I hope we wait to mid 2024 when armed with interim efficacy readouts. Hoping next cap raise will be much higher than the last 17c raise.
They’ve started historical studies with 1 patient finished screening. Not much new news, sadly delay of key clinic milestones, now confirmed to be shifted right to early next year due to IND being Q4; not sure if approval expected then too.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.010(8.33%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.0¢ | $383.6K | 3.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 169997 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 1549 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |